In a troubling revelation, internal records have unveiled a meeting between top officials from the Environmental Protection Agency (EPA) and Bayer’s CEO, Bill Anderson, which took place in June 2025. This meeting, held just before significant moves by the Trump administration to bolster Bayer’s position regarding its controversial glyphosate weed killer, has ignited concerns around the influence of corporate interests on public health regulations. As litigation mounts against Bayer for alleged cancer claims linked to its glyphosate products, the implications of this meeting are profound.
Meeting Details and Implications
The 17 June 2025 meeting saw Anderson and other Bayer executives engage directly with EPA officials, including administrator Lee Zeldin and several senior advisers. The agenda reportedly included discussions on “litigation” and “supreme court action,” particularly regarding the ongoing lawsuits from thousands of individuals who claim to have developed cancer after using glyphosate-based herbicides like Roundup.
These lawsuits hinge on allegations that Bayer failed to adequately inform consumers about the cancer risks associated with its products, a claim substantiated by numerous scientific studies over the years. Bayer’s strategy appears to be focused on obtaining a ruling from the Supreme Court that would shield it from liability, arguing that if the EPA does not mandate a cancer warning on glyphosate products, the company cannot be held responsible for not providing one.
Regulatory Actions Following the Meeting
Since this meeting, the Trump administration has taken a series of actions that appear to favour Bayer’s legal stance. Notably, in December 2025, the administration’s solicitor general, D. John Sauer, urged the Supreme Court to hear Bayer’s case, which the court subsequently agreed to, scheduling a hearing for April 2026. Furthermore, in a move that has raised eyebrows, the White House invoked the Defense Production Act in February 2026 to safeguard glyphosate production, effectively granting “immunity” to manufacturers like Bayer.
The administration’s support for Bayer culminated in an amicus brief filed by Sauer in March 2026, explicitly backing Bayer’s arguments before the Supreme Court. This trajectory, initiated just days after the meeting, has led to increasing scrutiny regarding the relationship between regulatory bodies and corporate interests.
Concerns from Advocacy Groups
Environmental health advocates have expressed alarm over the implications of such meetings. Nathan Donley, the environmental health science director for the Center for Biological Diversity, highlighted the troubling reality that political appointees at the EPA seem more committed to protecting corporate profits than safeguarding public health. He stated, “When the CEO of one of the largest companies in the world is meeting with political appointees in a US regulatory office, it shows just how much power and influence these corporations have on decisions that can have very real consequences for the health of all Americans.”
Legal experts like Whitney Di Bona have echoed these concerns, questioning whether the EPA has extended similar opportunities for dialogue to the thousands of individuals affected by glyphosate. This disparity raises fundamental questions about equity and transparency in regulatory processes.
The Broader Picture: Corporate Influence on Regulation
The meeting has sparked a broader discussion about the patterns of corporate influence in regulatory affairs. Naomi Oreskes, a Harvard professor, remarked that such high-level interactions reflect a troubling trend where industry leaders enjoy access to government officials that ordinary citizens do not. The stark contrast in engagement opportunities between corporate entities and public health advocates underscores systemic issues within the regulatory framework.
Zen Honeycutt, founder of Moms Across America, expressed disappointment but not surprise at the revelation, stating that coercive tactics by chemical companies on regulatory agencies have long been evident. Her organisation has repeatedly sought dialogue with the EPA over pesticide regulations yet has seen little action on their calls for reform.
Why it Matters
The implications of the EPA’s close relationship with Bayer extend beyond corporate interests; they pose a direct threat to public health. As litigation mounts against glyphosate, the question arises: will regulatory agencies prioritise the health of citizens or the profit margins of powerful corporations? This incident serves as a stark reminder of the need for transparency, accountability, and reform in how regulatory bodies engage with industries that have a profound impact on public health and safety. The stakes are high, and the public deserves an agency that prioritises its well-being over corporate profit.
